The COVID-19 pandemic created a critical need to find and connect participants with the right trials - quickly and efficiently. In the race to find treatments and vaccines, patient recruitment needed to be accelerated to accommodate a multitude of clinical trials that required various types of patients.

This case study reviews Labcorp MCS support of a rare genetic disease clinical trial in Singapore during the COVID-19 outbreak when "circuit breaker" measures were taken in the country

This case study reviews Labcorp MCS support of a global pulmonary inflammation clinical trial that was active in Australia, highlighting the benefits on a global level and the specific challenges faced in the Pacific country.

This case study shares how the Mobile Clinical Services team at Labcorp Drug Development helped enhance a sponsor's patient recruitment approach by providing site support services at key investigator sites.

A complete timeline for authorization of your biocide, from data gap analysis to dossier preparation.

EBF 2021 -- Multi-domain biologics can potentially induce anti-drug antibodies (ADA) with specificity to different domains.

BSI Congress 2021 -- Following the failure to predict the cytokine release syndrome (CRS) induced by TGN1412 in 2006, the need for improved predictive preclinical in vitro safety assessments has become a priority and a regulatory expectation.

It is imperative for marketing authorization holders (MAH) to analyze their existing operating models for maintaining mature products and consider how they can benefit from an integrated safety, regulatory and benefit-risk model.

Labcorp was approached by a company based in Europe, which produced pigments and needed to register six of these pigments in time for the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) 2018 submission deadline.